Erytech Pharma Overview
- Founded
-
2004
- Status
-
Public
- Employees
-
49
- Stock Symbol
-
ERYP
- Investments
-
1
- Share Price
-
$0.99
- (As of Tuesday Closing)
Erytech Pharma General Information
Description
Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.
Contact Information
- 60 Avenue Rockefeller
- Bâtiment Bioserra
- 69008 Lyon
- France
Erytech Pharma Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.99 | $0.99 | $0.30 - $1.50 | $33.9M | 34.1M | 263K | -$0.01 |
Erytech Pharma Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (40,467) | (40,467) | 31,259 | 133,532 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | 3,640 | 3,640 | (54,732) | (75,412) |
| Net Income | (240) | (240) | (63,604) | (83,556) |
| Total Assets | 49,128 | 49,128 | 75,596 | 98,892 |
| Total Debt | 14,549 | 14,549 | 28,730 | 33,760 |
Erytech Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Erytech Pharma Comparisons
Industry
Financing
Details
00000
000000
Erytech Pharma Competitors (69)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| TScan Therapeutics | Formerly VC-backed | Waltham, MA | 000 | 00000 | 00000000 | 00000 |
| 000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000 000000000 | Angel-Backed | New York, NY | 00000 | 0000000000 | 00000 | |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 000000&0 | |
| 00000 000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000000000 | 00000 |
Erytech Pharma Patents
Erytech Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021270347-A1 | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof | Pending | 11-May-2020 | 0000000000 | |
| CA-3178252-A1 | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof | Pending | 11-May-2020 | 0000000000 | |
| EP-4149440-A1 | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof | Pending | 11-May-2020 | 0000000000 | |
| EP-3880309-A1 | Synergistic combinations of methionine depletion agents and immune checkpoint modulators | Pending | 15-Nov-2018 | 00000000000 | |
| US-20210403571-A1 | Synergistic combinations of methionine depletion agents and immune checkpoint modulators | Pending | 15-Nov-2018 | A61K39/39 |
Erytech Pharma Executive Team (14)
Erytech Pharma Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Gil Beyen | Erytech Pharma | Chief Executive Officer & Board Member | 000 0000 |
| Hilde Windels | Self | Board Member | 000 0000 |
| Jean-Paul Kress MD | Self | Chairman & Board Member | 000 0000 |
| Martine George MD | Self | Board Member | 000 0000 |
| Philippe Archinard Ph.D | Self | Board Member | 000 0000 |
Erytech Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Erytech Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Erytech Pharma Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 00 | 16-Feb-2023 | 0000000000 | Drug Discovery | 000 00000 |
Erytech Pharma ESG
Risk Overview
Risk Rating
Updated December, 22, 2022
24.43 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,233
Rank
Percentile
Pharmaceuticals
Industry
00 of 866
Rank
Percentile
Biotechnology
Subindustry
00 of 382
Rank
Percentile
